FdaApplication
NDA 206619
Identifiers
- fda_app_no: NDA206619
Properties
| Property | Value |
|---|---|
| applicant_name | ABBVIE INC |
| application_type | NDA |
| approval_date | 2014-12-19 |
Revenue by product
VIEKIRA PAK (COPACKAGED)
| Period | Revenue |
|---|---|
| Q1 2020 | $5.0M* |
| Q4 2019 | $4.0M* |
| Q3 2019 | $3.0M* |
| Q2 2019 | $4.0M* |
| Q1 2019 | $25.0M* |
| Q4 2018 | $43.0M* |
| Q3 2018 | $23.0M* |
| Q2 2018 | $41.0M* |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients. A fourth quarter is the reported full year less nine months, since no filing states one.
Products (1)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| VIEKIRA PAK (COPACKAGED) | DASABUVIR SODIUM; OMBITASVIR, PARITAPREVIR, RITONAVIR | EQ 250MG BASE;12.5MG, 75MG, 50MG | TABLET;ORAL |
1 product